CVS Health Analyst Ratings
BofA Securities Maintains CVS Health(CVS.US) With Buy Rating, Maintains Target Price $77
Leerink Partners Maintains CVS Health(CVS.US) With Hold Rating
Bank of America Securities Remains a Buy on CVS Health (CVS)
Deutsche Bank Maintains CVS Health(CVS.US) With Hold Rating, Maintains Target Price $63
Evercore Maintains CVS Health(CVS.US) With Buy Rating, Maintains Target Price $62
Unlocking Value: A Buy Rating for CVS Health Amidst Potential Restructuring
Barclays Maintains CVS Health(CVS.US) With Hold Rating, Maintains Target Price $63
CVS Health (CVS) Gets a Hold From Barclays
Wolfe Research Adjusts CVS Health Price Target to $61 From $64
CVS Health Analyst Ratings
Stock Moves Reflect Downgrade for US Economic Growth Outlook - Goldman
CVS Health Analyst Ratings
CVS Health Analyst Ratings
RBC Capital Maintains CVS Health(CVS.US) With Buy Rating, Maintains Target Price $68
CVS Health (CVS) Receives a Buy From RBC Capital
Wells Fargo Maintains CVS Health(CVS.US) With Hold Rating, Maintains Target Price $61
Wells Fargo Sticks to Their Hold Rating for CVS Health (CVS)
Leerink Partners Maintains CVS Health(CVS.US) With Hold Rating, Maintains Target Price $60
Analysts Have Conflicting Sentiments on These Healthcare Companies: CVS Health (CVS), Pharvaris (PHVS) and United Therapeutics (UTHR)
No Data
No Data